The tumor-free survival rate was significantly higher for CD44 (−) GCTB patients than for CD44 (+) GCTB patients (P < 0.01, Figure 3C) while the tumor-free survival rate was obviously lower for VEGF (+) GCTB patients than for VEGF (−) GCTB patients (P < 0.05, Figure 3D). The gene discussed is CD44; the disease is neoplasm.